Sector Intelligence · MedTech · June 2026
MedTech Investment 2026
Market data, deal activity, regulatory landscape and investment opportunities in UK and global medical technology — for investors, family offices and private wealth owners.
Market Data
The Numbers Shaping MedTech in 2026
$80bn+
Disclosed global medtech M&A deal value in 2025, driven by Blackstone and TPG's $18.3 billion take-private of Hologic and major transactions from Abbott, BD and Stryker.
Source: MedDeviceGuide, EY, April 2026
$636m
Average deal size in medtech M&A in the year to June 2025 — capital concentrating around fewer, larger, higher-conviction bets as deal volume declined 41%.
Source: EY, MedTech Dive 2025
$7.4bn
US medtech PE deal flow through Q3 2025 across 75 investments — the second highest on record.
Source: PitchBook 2025
2026
Private equity expected to be the most active buyer in the sub-$50m bracket in UK medtech, with deep tech — robotics, bioelectronics and AI-driven devices — retaining premium valuation status.
Source: Nelson Advisors 2025
Investment Landscape
The MedTech Market in 2026
Medtech companies that have demonstrated the ability to deliver durable, above-market growth have been increasingly rewarded by investors, and M&A activity is expected to intensify around assets that can extend or accelerate growth trajectories. Acquirers continue to prioritise targets that accelerate digital transformation — including AI-driven analytics, robotics platforms and connected-care ecosystems.
PE deal activity in the medical device sector has been robust, even as other areas of life sciences struggle to obtain capital. PE investors have taken out or are in the process of buying five public medtech companies in 2025 — most recently Hologic, one of the few companies primarily focused on women's health, in an $18.3 billion deal by TPG and Blackstone.
In the UK, success in 2026 requires navigating the Triple Lock of NHS procurement, MHRA software as a medical device rules and pension fund capital requirements. Regulatory strategy is now as important as product strategy.
What Investors Are Targeting
Assets Attracting Capital in MedTech
AI-Enabled Devices
Technology will remain a key driver of transaction activity. Companies that demonstrate scalable digital infrastructure and measurable clinical or operational impact will be among the most sought-after targets. AI diagnostic devices, robotic surgical platforms and connected monitoring systems are commanding premium multiples.
Hard Tech Platforms
While consumer health apps face scepticism, hard tech — robotics, bioelectronics and AI-driven drug discovery — retains premium valuation status due to high barriers to entry and global strategic interest.
PE Buy-and-Build
Private equity buyers see significant opportunity to create value in medtech — shaping portfolios and driving value creation through improving operations. As incumbents reshape through divestitures, PE buyers can acquire those assets and leverage them into future growth.
Key Risks
Risks for MedTech Investors in 2026
- US tariffs on medical devices and EU-US trade tensions reshaping European medtech supply chains in 2026
- Chinese competition in imaging, surgical robotics and disposables creating both competitive threats and partnership opportunities
- MHRA and MDR regulatory classification challenges for AI-enabled devices
- NHS procurement cycles and reimbursement decisions creating UK market access uncertainty
Subscribe
Stay Informed on Healthcare Investment
Subscribe to Healthcare Investor Magazine — independent investment intelligence for investors, family offices and private wealth owners.
FAQs
Frequently Asked Questions
Related Sectors
Explore Other Investment Sectors
Published for informational purposes only. Does not constitute financial or investment advice. All data sourced from primary institutional sources as cited. Seek independent professional advice before making any investment decision.